Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer
Abstract Background Gut microbiome on predicting clinical responses to immune checkpoint inhibitors (ICIs) has been discussed in detail for decades, while microecological features of the lower respiratory tract within advanced non‐small‐cell lung cancer (NSCLC) are still relatively vague. Methods Du...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ctm2.70170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586788847222784 |
|---|---|
| author | Yong Zhang Xiang‐Xiang Chen Ruo Chen Ling Li Qing Ju Dan Qiu Yuan Wang Peng‐Yu Jing Ning Chang Min Wang Jian Zhang Zhi‐Nan Chen Ke Wang |
| author_facet | Yong Zhang Xiang‐Xiang Chen Ruo Chen Ling Li Qing Ju Dan Qiu Yuan Wang Peng‐Yu Jing Ning Chang Min Wang Jian Zhang Zhi‐Nan Chen Ke Wang |
| author_sort | Yong Zhang |
| collection | DOAJ |
| description | Abstract Background Gut microbiome on predicting clinical responses to immune checkpoint inhibitors (ICIs) has been discussed in detail for decades, while microecological features of the lower respiratory tract within advanced non‐small‐cell lung cancer (NSCLC) are still relatively vague. Methods During this study, 26 bronchoalveolar lavage fluids (BALF) from advanced NSCLC participants who received immune checkpoint inhibitor monotherapy were performed 16S rRNA sequencing and untargeted metabolome sequencing to identify differentially abundant microbes and metabolic characteristics. Additionally, inflammatory cytokines and chemokines were also launched in paired BALF and serum samples by immunoassays to uncover their underlying correlations. The omics data were separately analyzed and integrated by using multiple correlation coefficients. Multiplex immunohistochemical staining was then used to assess the immune cell infiltration after immune checkpoint blockade therapy. Results Lower respiratory tract microbiome diversity favoured preferred responses to ICIs. Microbial markers demonstrated microbial diversity overweight a single strain in favoured response to ICI therapy, where Bacillus matters. Sphingomonas and Sediminibacterium were liable to remodulate lipid and essential amino acid degradations to embrace progression after immunotherapies. Microbiome‐derived metabolites reshaped the immune microenvironment in the lower respiratory tract by releasing inflammatory cytokines and chemokines, which was partially achieved by metabolite‐mediated tumoral inflammatory products and reduction of CD8+ effective T cells and M1 phenotypes macrophages in malignant lesions. Conclusions This study provided a microecological landscape of the lower respiratory tract with advanced NSCLC to ICI interventions and presented a multidimensional perspective with favoured outcomes that may improve the predictive capacity of the localized microbiome in clinical practices. Highlights Alterations of the lower respiratory tract microbiome indicate different clinical responses to ICB within advanced NSCLC. Reduced microbial diversity of lower respiratory tracts impairs anti‐tumoral performances. Microbe‐derived metabolites perform as a dominant regulator to remodify the microecological environment in lower respiratory tracts. Multi‐omics sequencings of the lower respiratory tract possess the potential to predict the long‐term clinical responses to ICB among advanced NSCLC. |
| format | Article |
| id | doaj-art-58695c87d0424be791ffc1fff8f15f7b |
| institution | Kabale University |
| issn | 2001-1326 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Medicine |
| spelling | doaj-art-58695c87d0424be791ffc1fff8f15f7b2025-01-25T04:00:38ZengWileyClinical and Translational Medicine2001-13262025-01-01151n/an/a10.1002/ctm2.70170Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancerYong Zhang0Xiang‐Xiang Chen1Ruo Chen2Ling Li3Qing Ju4Dan Qiu5Yuan Wang6Peng‐Yu Jing7Ning Chang8Min Wang9Jian Zhang10Zhi‐Nan Chen11Ke Wang12Department of Cell BiologyNational Translational Science Center for Molecular MedicineFourth Military Medical UniversityXi'anChinaDepartment of Cell BiologyNational Translational Science Center for Molecular MedicineFourth Military Medical UniversityXi'anChinaDepartment of Cell BiologyNational Translational Science Center for Molecular MedicineFourth Military Medical UniversityXi'anChinaDepartment of Cell BiologyNational Translational Science Center for Molecular MedicineFourth Military Medical UniversityXi'anChinaDepartment of Pulmonary and Critical Care of MedicineThe First Affiliated Hospital of Fourth Military Medical UniversityXi'anChinaDepartment of Pulmonary and Critical Care of MedicineThe First Affiliated Hospital of Fourth Military Medical UniversityXi'anChinaDepartment of MicrobiologySchool of Basic MedicineFourth Military Medical UniversityXi'anChinaDepartment of Thoracic SurgeryThe Second Affiliated Hospital of Fourth Military Medical UniversityXi'anChinaDepartment of Pulmonary and Critical Care of MedicineThe First Affiliated Hospital of Fourth Military Medical UniversityXi'anChinaDepartment of Pulmonary and Critical Care of MedicineThe First Affiliated Hospital of Fourth Military Medical UniversityXi'anChinaDepartment of Pulmonary and Critical Care of MedicineThe First Affiliated Hospital of Fourth Military Medical UniversityXi'anChinaDepartment of Cell BiologyNational Translational Science Center for Molecular MedicineFourth Military Medical UniversityXi'anChinaDepartment of Cell BiologyNational Translational Science Center for Molecular MedicineFourth Military Medical UniversityXi'anChinaAbstract Background Gut microbiome on predicting clinical responses to immune checkpoint inhibitors (ICIs) has been discussed in detail for decades, while microecological features of the lower respiratory tract within advanced non‐small‐cell lung cancer (NSCLC) are still relatively vague. Methods During this study, 26 bronchoalveolar lavage fluids (BALF) from advanced NSCLC participants who received immune checkpoint inhibitor monotherapy were performed 16S rRNA sequencing and untargeted metabolome sequencing to identify differentially abundant microbes and metabolic characteristics. Additionally, inflammatory cytokines and chemokines were also launched in paired BALF and serum samples by immunoassays to uncover their underlying correlations. The omics data were separately analyzed and integrated by using multiple correlation coefficients. Multiplex immunohistochemical staining was then used to assess the immune cell infiltration after immune checkpoint blockade therapy. Results Lower respiratory tract microbiome diversity favoured preferred responses to ICIs. Microbial markers demonstrated microbial diversity overweight a single strain in favoured response to ICI therapy, where Bacillus matters. Sphingomonas and Sediminibacterium were liable to remodulate lipid and essential amino acid degradations to embrace progression after immunotherapies. Microbiome‐derived metabolites reshaped the immune microenvironment in the lower respiratory tract by releasing inflammatory cytokines and chemokines, which was partially achieved by metabolite‐mediated tumoral inflammatory products and reduction of CD8+ effective T cells and M1 phenotypes macrophages in malignant lesions. Conclusions This study provided a microecological landscape of the lower respiratory tract with advanced NSCLC to ICI interventions and presented a multidimensional perspective with favoured outcomes that may improve the predictive capacity of the localized microbiome in clinical practices. Highlights Alterations of the lower respiratory tract microbiome indicate different clinical responses to ICB within advanced NSCLC. Reduced microbial diversity of lower respiratory tracts impairs anti‐tumoral performances. Microbe‐derived metabolites perform as a dominant regulator to remodify the microecological environment in lower respiratory tracts. Multi‐omics sequencings of the lower respiratory tract possess the potential to predict the long‐term clinical responses to ICB among advanced NSCLC.https://doi.org/10.1002/ctm2.70170advanced non‐small‐cell lung cancerclinical outcomesimmune checkpoint blockade therapylower respiratory tract microbiomemulti‐omics analysis |
| spellingShingle | Yong Zhang Xiang‐Xiang Chen Ruo Chen Ling Li Qing Ju Dan Qiu Yuan Wang Peng‐Yu Jing Ning Chang Min Wang Jian Zhang Zhi‐Nan Chen Ke Wang Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer Clinical and Translational Medicine advanced non‐small‐cell lung cancer clinical outcomes immune checkpoint blockade therapy lower respiratory tract microbiome multi‐omics analysis |
| title | Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer |
| title_full | Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer |
| title_fullStr | Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer |
| title_full_unstemmed | Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer |
| title_short | Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer |
| title_sort | lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non small cell lung cancer |
| topic | advanced non‐small‐cell lung cancer clinical outcomes immune checkpoint blockade therapy lower respiratory tract microbiome multi‐omics analysis |
| url | https://doi.org/10.1002/ctm2.70170 |
| work_keys_str_mv | AT yongzhang lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT xiangxiangchen lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT ruochen lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT lingli lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT qingju lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT danqiu lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT yuanwang lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT pengyujing lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT ningchang lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT minwang lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT jianzhang lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT zhinanchen lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer AT kewang lowerrespiratorytractmicrobiomedysbiosisimpairsclinicalresponsestoimmunecheckpointblockadeinadvancednonsmallcelllungcancer |